Fuan Pharmaceutical Industry: Its subsidiary, Chuyao Pharmaceutical Industry, has received the drug registration certificate.

date
28/07/2025
Fuan Pharmaceutical announced that its wholly-owned subsidiary, Chiju Pharmaceutical, recently received a drug registration certificate issued by the National Medical Products Administration. The drug is named Adenosine Diammonium Disulfate for Injection, with a specification of 0.5g, and the approval number is H20254936. This drug is suitable for cholestasis before cirrhosis, cholestasis caused by cirrhosis, and intrahepatic cholestasis of pregnancy. The acquisition of the above drug registration certificate will further enrich the product line of the subsidiary and enhance its market competitiveness. However, due to factors such as changes in medical policies and market environments, there is uncertainty about the production, sales, and specific impact on the company's performance of the above-mentioned products.